Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine

Ozkaya,Sevket; Findik,Serhat; Dirican,Adem; Atici,Atilla Güven

doi:10.3892/etm.2012.714

December 2012 Volume 4 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December 2012 Volume 4 Issue 6

Full Size Image

Article

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine

Authors:
- Sevket Ozkaya
- Serhat Findik
- Adem Dirican
- Atilla Güven Atici
View Affiliations / Copyright

Affiliations: Department of Pulmonary Medicine, Faculty of Medicine, Rize University, Rize, Turkey, Department of Pulmonary Medicine, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey, Department of Pulmonary Medicine, Samsun Medical Park Hospital, Samsun, Turkey
Pages: 1035-1038
|
Published online on: September 18, 2012

https://doi.org/10.3892/etm.2012.714
Expand metrics +

Abstract

Limited data exist concerning the long-term (≥5 year) survival rates of patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) receiving chemotherapy. We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. The study included 141 patients, and all patients were followed up from the time of diagnosis until death. The median age of the patients was 59.1±9.9 years. The male-to-female ratio was 124/17; 62.4% of the patients had stage IIIB and 37.6% had stage IV NSCLC. Squamous cell carcinoma, adenocarcinoma and undifferentiated NSCLC subtypes accounted for 69.5, 17.7 and 12.7% of the cases, respectively. The overall response rate was 32.6% and the median survival time was 12.3 months (95% CI, 10.2-14.5). The median survival times for stages IIIB and IV were 12.6±1.4 and 11.9±1.7 months, respectively. The 1-, 2-, 3- and 5-year survival rates were 33, 7.5, 4.3 and 2.8%, respectively. In conclusion, cisplatin-based new-generation cytotoxic agents for combined modality therapy offer an increased hope of long-term survival for patients with locally advanced and advanced NSCLC.

View Figures

View References

1	Molina JR, Adjei AA and Jett JR: Advances in chemotherapy of non-small cell lung cancer. Chest. 130:1211–1219. 2006. View Article : Google Scholar : PubMed/NCBI
2	Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
3	De Cos Escuin JS, Vecente CD, Penafiel JC, Miranda JAR, Gonzalez MAS and Jimenez JFM: Overall long-term survival in lung cancer analyzed in 610 unselected patients. Arch Bronconeumol. 40:268–274. 2004.PubMed/NCBI
4	Fry WA, Phillips JL and Menck HR: Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 86:1867–1876. 1999.PubMed/NCBI
5	Wang T, Nelson RA, Bogardus A and Granis FW Jr: Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 116:1518–1525. 2010.PubMed/NCBI
6	Hagerty RG, Butow PN, Ellis PA, et al: Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol. 22:1721–1730. 2004. View Article : Google Scholar : PubMed/NCBI
7	Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, et al: Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer. 47:85–91. 2005. View Article : Google Scholar : PubMed/NCBI
8	Satoh H, Ishikawa H, Ohara G, Kagohashi K, Kurishima K, Ohtsuka M and Hizawa N: Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 27:4457–4460. 2007.PubMed/NCBI
9	Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M and Yamamoto N: Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer. 67:120–123. 2010.PubMed/NCBI
10	Southern Italy Cooperative Oncology Group (SICOG): Gemcitabine plus cisplatin combinations in advanced non-small cell lung cancer. Anticancer Drugs. 11:S23–S27. 2000.
11	Huisman C, Giaccone G, van Groeningen CJ, Sutedja G, Postmus PE and Smit EF: Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. Lung Cancer. 33:267–275. 2001. View Article : Google Scholar : PubMed/NCBI
12	Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 17:3522–3530. 1999.PubMed/NCBI
13	Cardenal F, Lopez-Cabrerizo M, Anton A, Alberola V, Massuti B, Carrato A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 17:12–18. 1999.PubMed/NCBI